Please assess the completion status of the following clinical trial:

Trial Title: The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult subjects aged ≥18 years requiring elective/non-emergent open or laparoscopic general, gynecological, or cardiothoracic surgical procedures.~2. Subject or authorized representative has signed the approved Informed Consent.~3. Subject(s) whose platelet count is ≥100,000 per microliter and International Normalized Ratio (INR) is \<1.5 prior to 24 hours of surgery.~4. Presence of an appropriate TBS identified intra-operatively by the surgeon.~5. Subject(s) undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to TBS identification and treatment.~Exclusion Criteria:~1. Female subjects who are pregnant or nursing.~2. Subject on heparin within 12 hours prior to surgery, or oral Coumadin (warfarin) and/or Factor Xa inhibitors within 3 days prior to surgery.~3. Subject on antiplatelet/P2Y12 inhibitors medication 5 days prior to surgery;~4. Subject is currently participating or plans to participate in any other investigational product or drug trial without prior approval from the Sponsor.~5. Subjects who are known, current alcohol and/or drug abusers.~6. Subjects with any pre-operative findings identified by the surgeon that may preclude conduct of the study procedure.~7. Subjects with any intra-operative findings identified by the surgeon that may preclude the use of study product.~8. Subject with TBS in an actively infected field (Class III Contaminated or Class IV Dirty or Infected; see Appendix 1).~9. TBS is on arteries or veins where application of SURGICEL Powder would present a risk of introducing the study product into an open blood vessel.~10. Major arterial or venous bleeding or major defects in arteries and veins.~11. TBS where silver nitrate or any other escharotic chemicals have been applied.~12. TBS is in, around, or in proximity to foramina in bone, or areas of bony

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SURGICEL Powder (Type: EXPERIMENTAL): SURGICEL Powder is an absorbable hemostat that is oxidized regenerated cellulose in a powder form
- SURGICEL Original (Type: ACTIVE_COMPARATOR): SURGICEL Original is an bsorbable hemostat that is oxidized regenerated cellulose in a fabric form

Based on this trial design, predict the completion outcome and termination type (if applicable).